Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/09/2020 | Series C | $60MM | $xx.xx | $511MM | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
14,388,490
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences
|
||||||
07/30/2018 | Series B-2 | $20.3MM | $xx.xx | $233.69MM | Nan Fung Life Sciences, Lam Research, Hillhouse Capital Group, Domain Associates, Decheng Capital, ARCH Venture Partners, Biomatics Capital Partners, Altitude Life Science Ventures | |
Price per Share
$xx.xx
Shares Outstanding
7,132,316
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Nan Fung Life Sciences, Lam Research, Hillhouse Capital Group, Domain Associates, Decheng Capital, ARCH Venture Partners, Biomatics Capital Partners, Altitude Life Science Ventures
|
||||||
07/30/2018 | Series B-1 | $40.2MM | $xx.xx | $233.69MM | Nan Fung Life Sciences, Lam Research, Hillhouse Capital Group, Domain Associates, Decheng Capital, ARCH Venture Partners, Biomatics Capital Partners, Altitude Life Science Ventures | |
Price per Share
$xx.xx
Shares Outstanding
21,185,768
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Nan Fung Life Sciences, Lam Research, Hillhouse Capital Group, Domain Associates, Decheng Capital, ARCH Venture Partners, Biomatics Capital Partners, Altitude Life Science Ventures
|
||||||
01/01/2016 | Series A-2 | $13.04MM | $xx.xx | $75.5MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,873,967
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
01/01/2016 | Series A-1 | $19.75MM | $xx.xx | $75.5MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
21,944,021
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|